BEIJING: Pfizer Inc has decided to stop producing biosimilar products in China and sell a unit in the eastern city of Hangzhou to WuXi Biologics Inc, the US drugmaker said on Wednesday.The pharmaceutical industry increasingly relies for its profits on costly biologic drugs, made from living organisms that are tougher and more expensive to make than conventional medicines with chemical ingredients.“The site was planned to manufacture three biosimilars for the China market,“ the company said in a response to Reuters.“Pfizer commercially and technically evaluated other products for the site but none reached the level of activity for the scale of the site.”Neither Pfizer nor WuXi disclosed the d
Hence then, the article about pfizer to halt biosimilar output in china sell assets to wuxi biologics was published today ( ) and is available onDaily Sun ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Pfizer to halt biosimilar output in China, sell assets to WuXi Biologics )